Exchange: NASDAQ·Updated 07:34 PM EDT
PTCT logo

PTCTPTC Therapeutics Inc

$76.82
$1.63
(2.08%)
Today
Closed $76.82
$0.00
(0.00%)
After Hours
EarningsJul 30
Mkt Cap$6.37B
Vol838,164.00
News
all
press releases
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director Hamilton Lane Board Elects Michael Schmertzler as New Independent Director PR Newswire CONSHOHOCKEN, Pa., July 23, 2026 CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm...
PR Newswire
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Zacks
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
Zacks
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
Zacks
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 PR Newswire WARREN, N.J., July 16, 2026 WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...
PR Newswire
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
Key PointsThe transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25...
Nasdaq News: Markets
Reasons Why Investors Should Consider Betting on PTC Stock Now
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Zacks
Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
Zacks
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.
Zacks
<
1
2
...
>

Advertisement|Remove ads.